Raja Mudad is an Oncology physician affiliated with University of Miami. OpenAlex indexes 48 publications with 589 citations (h-index 16); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1475 NW 12th Ave
Miami, FL 331361002
Telephone
305-243-4900Provider last certified this registry record 17 Jun 2022.
Clinical trials
- S0310: Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Bronchoalveolar Lung Cancer
Sponsor: SWOG Cancer Research Network
- Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer
Sponsor: Tulane University Health Sciences Center
- S0022:Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer
Sponsor: SWOG Cancer Research Network
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
58 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Healthcare Solutions, Inc.Program year202513 payments
- E.R. Squibb & Sons, L.L.C.Program year202512 payments
- ABBVIE INC.Program year20258 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
45.8%Serotonin-3 Receptor Antagonist18.8%Ondansetron Hcl100%Part D≥46 patientsCorticosteroid12.6%Prednisone100%Part D≥16 patients+ 3 more classes in this area
Nervous system
36.2%Benzodiazepine8.8%Alprazolam64%Lorazepam36%Part D<11 patientsgamma-Aminobutyric Acid A Receptor Positive Modulator8.8%Zolpidem Tartrate100%Part D<11 patients+ 4 more classes in this area
Cancer & immunology
10.2%Kinase inhibitor10.2%Tagrisso68%Lorbrena32%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer
British Journal of Cancer
2019 - <p>Brigatinib for <em>ALK</em>-positive metastatic non-small-cell lung cancer: design, development and place in therapy</p>
Drug Design Development and Therapy
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Myerburg, MD
University of Miami
Thomas Hooton, MD
University of Miami
Harry Flynn, MD
University of Miami
Alan Wein, MD
University of Miami
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”